In the last 12 months, insiders at Aquestive Therapeutics, Inc. ($AQST) filed 130 transactions with the SEC: 0 open-market purchases totaling $0 and 18 sales totaling $3,773,709. Net insider sentiment: net selling.
Aquestive Therapeutics, Inc. operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Barber Daniel (President and CEO) — 13 transactions totaling $1,990,757
- Jung Cassie (Chief Operating Officer) — 17 transactions totaling $1,196,117
- Schobel Alexander Mark (Chief Innovation/Tech Officer) — 6 transactions totaling $505,520
- TOTH A ERNEST JR (Chief Financial Officer) — 7 transactions totaling $293,256
- Kraus Carl N (Chief Medical Officer) — 8 transactions totaling $242,712
View all SEC Filings for Aquestive Therapeutics, Inc. (AQST).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 9, 2026 | Greenhawt Matthew J. | Chief Medical Officer | A | Non-Qualified Stock Option (right to buy) | 50000 | $4.29 | 50,000.0000 | 122,003,113 | 9999.99% | 0.04% |
| March 9, 2026 | Barber Daniel | President and CEO | A | Non-Qualified Stock Option (right to buy) | 523000 | $4.29 | 523,000.0000 | 122,003,113 | 9999.99% | 0.43% |
| March 10, 2026 | Barber Daniel | President and CEO | S | Common Stock | 180677 | $4.17 | 1,004,753.0000 | 122,003,113 | 15.24% | 0.15% |
| March 9, 2026 | Barber Daniel | President and CEO | A | Common Stock | 262000 | $0.00 | 1,185,430.0000 | 122,003,113 | 28.37% | 0.21% |
| March 9, 2026 | Boyd Peter E. | Chief People Officer | A | Non-Qualified Stock Option (right to buy) | 42500 | $4.29 | 42,500.0000 | 122,003,113 | 9999.99% | 0.03% |
| March 10, 2026 | Boyd Peter E. | Chief People Officer | S | Common Stock | 29814 | $4.17 | 338,509.0000 | 122,003,113 | 8.09% | 0.02% |
| March 9, 2026 | Boyd Peter E. | Chief People Officer | A | Common Stock | 80000 | $0.00 | 368,323.0000 | 122,003,113 | 27.75% | 0.07% |
| March 9, 2026 | Davis Matthew W. | Chief Development Officer | A | Non-Qualified Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 122,003,113 | 9999.99% | 0.04% |
| March 9, 2026 | Davis Matthew W. | Chief Development Officer | A | Common Stock | 50000 | $0.00 | 100,000.0000 | 122,003,113 | 100.00% | 0.04% |
| March 9, 2026 | Jung Cassie | Chief Operating Officer | A | Non-Qualified Stock Option (right to buy) | 42500 | $0.00 | 42,500.0000 | 122,003,113 | 9999.99% | 0.03% |
| March 10, 2026 | Jung Cassie | Chief Operating Officer | S | Common Stock | 45791 | $4.17 | 276,980.0000 | 122,003,113 | 14.19% | 0.04% |
| March 9, 2026 | Jung Cassie | Chief Operating Officer | A | Common Stock | 80000 | $0.00 | 322,771.0000 | 122,003,113 | 32.95% | 0.07% |
| March 9, 2026 | BRAENDER LORI J | Chief Legal Officer | A | Common Stock | 80000 | $0.00 | 482,981.0000 | 122,003,113 | 19.85% | 0.07% |
| March 9, 2026 | Greenhawt Matthew J. | Chief Medical Officer | A | Common Stock | 75000 | $0.00 | 77,000.0000 | 122,003,113 | 3750.00% | 0.06% |
| March 9, 2026 | Korczynski Sherry | Chief Commercial Officer | A | Non-Qualified Stock Option (right to buy) | 42500 | $4.29 | 42,500.0000 | 122,003,113 | 9999.99% | 0.03% |
| March 10, 2026 | Korczynski Sherry | Chief Commercial Officer | S | Common Stock | 15741 | $4.17 | 241,117.0000 | 122,003,113 | 6.13% | 0.01% |
| March 9, 2026 | Korczynski Sherry | Chief Commercial Officer | A | Common Stock | 75000 | $0.00 | 256,858.0000 | 122,003,113 | 41.24% | 0.06% |
| March 9, 2026 | TOTH A ERNEST JR | Chief Financial Officer | A | Non-Qualified Stock Option (right to buy) | 70000 | $0.00 | 70,000.0000 | 122,003,113 | 9999.99% | 0.06% |
| March 10, 2026 | TOTH A ERNEST JR | Chief Financial Officer | S | Common Stock | 58254 | $4.17 | 376,112.0000 | 122,003,113 | 13.41% | 0.05% |
| March 9, 2026 | TOTH A ERNEST JR | Chief Financial Officer | A | Common Stock | 95000 | $0.00 | 434,366.0000 | 122,003,113 | 27.99% | 0.08% |
| March 9, 2026 | Cioffi Melina | SVP, Regulatory Affairs | A | Non-Qualified Stock Option (right to buy) | 75000 | $4.29 | 75,000.0000 | 122,003,113 | 9999.99% | 0.06% |
| March 10, 2026 | Cioffi Melina | SVP, Regulatory Affairs | S | Common Stock | 25311 | $4.17 | 274,867.0000 | 122,003,113 | 8.43% | 0.02% |
| March 9, 2026 | Cioffi Melina | SVP, Regulatory Affairs | A | Common Stock | 100000 | $0.00 | 300,178.0000 | 122,003,113 | 49.96% | 0.08% |
| March 9, 2026 | BRAENDER LORI J | Chief Legal Officer | A | Non-Qualified Stock Option (right to buy) | 50000 | $4.29 | 50,000.0000 | 122,003,113 | 9999.99% | 0.04% |
| March 10, 2026 | BRAENDER LORI J | Chief Legal Officer | S | Common Stock | 40102 | $4.17 | 442,879.0000 | 122,003,113 | 8.30% | 0.03% |
| Dec. 4, 2025 | Boyd Peter E. | Chief People Officer | A | Common Stock | 20000 | $0.00 | 288,323.0000 | 122,003,113 | 7.45% | 0.02% |
| Dec. 2, 2025 | Cioffi Melina | SVP, Regulatory Affairs | F | Common Stock | 2083 | $5.93 | 200,178.0000 | 122,003,113 | 1.03% | 0.00% |
| Nov. 10, 2025 | Davis Matthew W. | Chief Development Officer | A | Common Stock | 50000 | $0.00 | 50,000.0000 | 122,003,113 | 9999.99% | 0.04% |
| Nov. 10, 2025 | Davis Matthew W. | Chief Development Officer | A | Non-Qualified Stock Option (right to buy) | 50000 | $0.00 | 50,000.0000 | 122,003,113 | 9999.99% | 0.04% |
| Oct. 15, 2025 | Boyd Peter E. | See Remarks | S | Common Stock | 10000 | $7.00 | 268,323.0000 | 98,871,369 | 3.59% | 0.01% |
| Oct. 15, 2025 | Jung Cassie | Chief Operating Officer | S | Common Stock | 67575 | $7.01 | 242,771.0000 | 98,871,369 | 21.77% | 0.07% |
| Oct. 15, 2025 | Jung Cassie | Chief Operating Officer | M | Non-Qualified Stock Option (right to buy) | 25000 | $0.00 | 0.0000 | 98,871,369 | 100.00% | 0.03% |
| Oct. 15, 2025 | Kraus Carl N | Chief Medical Officer | S | Common Stock | 20272 | $7.00 | 282,475.0000 | 98,871,369 | 6.70% | 0.02% |
| Oct. 15, 2025 | Jung Cassie | Chief Operating Officer | M | Common Stock | 25000 | $3.10 | 310,346.0000 | 98,871,369 | 8.76% | 0.03% |
| Sept. 26, 2025 | Boyd Peter E. | See Remarks | S | Common Stock | 10000 | $6.30 | 278,323.0000 | 98,871,369 | 3.47% | 0.01% |
| Sept. 26, 2025 | Barber Daniel | President and CEO | S | Common Stock | 91343 | $6.03 | 923,430.0000 | 98,871,369 | 9.00% | 0.09% |
| Sept. 19, 2025 | Barber Daniel | President and CEO | S | Common Stock | 400 | $6.00 | 1,014,773.0000 | 98,871,369 | 0.04% | 0.00% |
| Sept. 4, 2025 | Jung Cassie | Chief Operating Officer | S | Common Stock | 62180 | $5.00 | 285,346.0000 | 98,871,369 | 17.89% | 0.06% |
| Sept. 4, 2025 | Jung Cassie | Chief Operating Officer | M | Non-Qualified Stock Option (right to buy) | 25000 | $0.00 | 0.0000 | 98,871,369 | 100.00% | 0.03% |
| Sept. 4, 2025 | Jung Cassie | Chief Operating Officer | M | Non-Qualified Stock Option (right to buy) | 25000 | $0.00 | 0.0000 | 98,871,369 | 100.00% | 0.03% |
| Sept. 5, 2025 | Boyd Peter E. | See Remarks | S | Common Stock | 15000 | $5.30 | 288,323.0000 | 98,871,369 | 4.95% | 0.02% |
| Sept. 4, 2025 | Jung Cassie | Chief Operating Officer | M | Common Stock | 25000 | $3.15 | 322,526.0000 | 98,871,369 | 8.40% | 0.03% |
| Sept. 4, 2025 | Jung Cassie | Chief Operating Officer | M | Common Stock | 25000 | $0.71 | 347,526.0000 | 98,871,369 | 7.75% | 0.03% |
| Aug. 14, 2025 | Korczynski Sherry | Chief Commercial Officer | A | Common Stock | 25000 | $0.00 | 181,858.0000 | 98,871,369 | 15.94% | 0.03% |
| Aug. 9, 2025 | Kraus Carl N | Chief Medical Officer | F | Common Stock | 10819 | $3.90 | 302,747.0000 | 98,871,369 | 3.45% | 0.01% |
| June 11, 2025 | Jenkins Abigail L. | Not found | A | Non-Qualified Stock Option (right to buy) | 42000 | $3.41 | 42,000.0000 | 98,871,369 | 50.00% | 0.04% |
| June 11, 2025 | MORRIS TIMOTHY E | Not found | A | Stock Option (right to purchase) | 42000 | $3.41 | 42,000.0000 | 98,871,369 | 9999.99% | 0.04% |
| June 11, 2025 | Krop Julie | Not found | A | Stock Option (Right to Purchase) | 42000 | $3.41 | 42,000.0000 | 98,871,369 | 9999.99% | 0.04% |
| June 11, 2025 | BROWN GREGORY B | Not found | A | Stock Option (Right to Purchase) | 42000 | $3.41 | 42,000.0000 | 98,871,369 | 9999.99% | 0.04% |
| June 11, 2025 | Taglietti Marco | Not found | A | Stock Option (Right to Purchase) | 42000 | $3.41 | 42,000.0000 | 98,871,369 | 9999.99% | 0.04% |
| June 11, 2025 | Cochran John | Not found | A | Stock Option (Right to Purchase) | 42000 | $3.41 | 42,000.0000 | 98,871,369 | 9999.99% | 0.04% |
| June 9, 2025 | Korczynski Sherry | SVP Sales and Marketing | F | Common Stock | 2714 | $3.54 | 156,858.0000 | 98,871,369 | 1.70% | 0.00% |
| May 15, 2025 | Cioffi Melina | SVP, Regulatory Affairs | A | Common Stock | 20000 | $0.00 | 202,261.0000 | 98,871,369 | 10.97% | 0.02% |
| March 7, 2025 | BRAENDER LORI J | Chief Legal Officer | F | Common Stock | 9592 | $2.65 | 413,639.0000 | 98,871,369 | 2.27% | 0.01% |
| March 7, 2025 | Wargacki Stephen | Chief Science Officer | A | Common Stock | 115000 | $0.00 | 376,414.0000 | 98,871,369 | 43.99% | 0.12% |
| March 7, 2025 | Wargacki Stephen | Chief Science Officer | F | Common Stock | 12859 | $2.65 | 363,555.0000 | 98,871,369 | 3.42% | 0.01% |
| March 9, 2025 | Wargacki Stephen | Chief Science Officer | F | Common Stock | 15431 | $2.65 | 348,124.0000 | 98,871,369 | 4.24% | 0.02% |
| March 10, 2025 | Wargacki Stephen | Chief Science Officer | F | Common Stock | 4572 | $2.54 | 343,552.0000 | 98,871,369 | 1.31% | 0.00% |
| March 7, 2025 | Wargacki Stephen | Chief Science Officer | A | Non-Qualified Stock Option (right to buy) | 65000 | $0.00 | 65,000.0000 | 98,871,369 | 9999.99% | 0.07% |
| March 7, 2025 | Jung Cassie | Chief Operating Officer | A | Common Stock | 80000 | $0.00 | 315,066.0000 | 98,871,369 | 34.03% | 0.08% |
| March 7, 2025 | Jung Cassie | Chief Operating Officer | F | Common Stock | 7361 | $2.65 | 307,705.0000 | 98,871,369 | 2.34% | 0.01% |
| March 9, 2025 | Jung Cassie | Chief Operating Officer | F | Common Stock | 7997 | $2.65 | 299,708.0000 | 98,871,369 | 2.60% | 0.01% |
| March 10, 2025 | Jung Cassie | Chief Operating Officer | F | Common Stock | 2182 | $2.54 | 297,526.0000 | 98,871,369 | 0.73% | 0.00% |
| March 7, 2025 | Jung Cassie | Chief Operating Officer | A | Non-Qualified Stock Option (right to buy) | 40000 | $0.00 | 40,000.0000 | 98,871,369 | 9999.99% | 0.04% |
| March 7, 2025 | TOTH A ERNEST JR | Chief Financial Officer | A | Common Stock | 110000 | $0.00 | 358,295.0000 | 98,871,369 | 44.30% | 0.11% |
| March 7, 2025 | TOTH A ERNEST JR | Chief Financial Officer | F | Common Stock | 10193 | $2.65 | 348,102.0000 | 98,871,369 | 2.84% | 0.01% |
| March 9, 2025 | TOTH A ERNEST JR | Chief Financial Officer | F | Common Stock | 8736 | $2.65 | 339,366.0000 | 98,871,369 | 2.51% | 0.01% |
| March 7, 2025 | TOTH A ERNEST JR | Chief Financial Officer | A | Non-Qualified Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 98,871,369 | 9999.99% | 0.06% |
| March 7, 2025 | Kraus Carl N | Chief Medical Officer | A | Common Stock | 70000 | $0.00 | 321,681.0000 | 98,871,369 | 27.81% | 0.07% |
| March 7, 2025 | Kraus Carl N | Chief Medical Officer | F | Common Stock | 8115 | $2.65 | 313,566.0000 | 98,871,369 | 2.52% | 0.01% |
| March 7, 2025 | Kraus Carl N | Chief Medical Officer | A | Non-Qualified Stock Option (right to buy) | 30000 | $0.00 | 30,000.0000 | 98,871,369 | 9999.99% | 0.03% |
| March 7, 2025 | Korczynski Sherry | SVP Sales and Marketing | A | Common Stock | 90000 | $0.00 | 165,000.0000 | 98,871,369 | 120.00% | 0.09% |
| March 7, 2025 | Korczynski Sherry | SVP Sales and Marketing | F | Common Stock | 5428 | $2.65 | 159,572.0000 | 98,871,369 | 3.29% | 0.01% |
| March 7, 2025 | Korczynski Sherry | SVP Sales and Marketing | A | Non-Qualified Stock Option (right to buy) | 35000 | $0.00 | 35,000.0000 | 98,871,369 | 9999.99% | 0.04% |
| March 7, 2025 | BRAENDER LORI J | Chief Legal Officer | A | Common Stock | 110000 | $0.00 | 423,231.0000 | 98,871,369 | 35.12% | 0.11% |
| March 9, 2025 | BRAENDER LORI J | Chief Legal Officer | F | Common Stock | 10658 | $2.65 | 402,981.0000 | 98,871,369 | 2.58% | 0.01% |
| March 7, 2025 | BRAENDER LORI J | Chief Legal Officer | A | Non-Qualified Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 98,871,369 | 9999.99% | 0.06% |
| March 7, 2025 | Boyd Peter E. | See Remark | A | Common Stock | 80000 | $0.00 | 317,628.0000 | 98,871,369 | 33.67% | 0.08% |
| March 7, 2025 | Boyd Peter E. | See Remark | F | Common Stock | 6624 | $2.65 | 311,004.0000 | 98,871,369 | 2.09% | 0.01% |
| March 9, 2025 | Boyd Peter E. | See Remark | F | Common Stock | 7681 | $2.65 | 303,323.0000 | 98,871,369 | 2.47% | 0.01% |
| March 7, 2025 | Boyd Peter E. | See Remark | A | Non-Qualified Stock Option (right to buy) | 40000 | $0.00 | 40,000.0000 | 98,871,369 | 9999.99% | 0.04% |
| March 7, 2025 | Barber Daniel | President and CEO | A | Common Stock | 272000 | $0.00 | 1,098,478.0000 | 98,871,369 | 32.91% | 0.28% |
| March 7, 2025 | Barber Daniel | President and CEO | F | Common Stock | 29307 | $2.65 | 1,069,171.0000 | 98,871,369 | 2.67% | 0.03% |
| March 9, 2025 | Barber Daniel | President and CEO | F | Common Stock | 53998 | $2.65 | 1,015,173.0000 | 98,871,369 | 5.05% | 0.05% |
| March 7, 2025 | Barber Daniel | President and CEO | A | Non-Qualified Stock Option (right to buy) | 408000 | $0.00 | 408,000.0000 | 98,871,369 | 9999.99% | 0.41% |
| Dec. 2, 2024 | BRATTON DOUGLAS K | Not found | G | Common Stock | 40000 | $0.00 | 10,026,111.0000 | 0 | 0.40% | 0.00% |
| Nov. 26, 2024 | Jung Cassie | Chief Operating Officer | S | Common Stock | 44 | $4.87 | 235,066.0000 | 0 | 0.02% | 0.00% |
| March 9, 2024 | Schobel Alexander Mark | Chief Innovation/Tech Officer | F | Common Stock | 9645 | $4.88 | 980,726.0000 | 0 | 0.97% | 0.00% |
| March 9, 2024 | Jung Cassie | SVP, Operations | F | Common Stock | 14120 | $4.88 | 235,110.0000 | 0 | 5.67% | 0.00% |
| March 9, 2024 | Wargacki Stephen | Chief Science Officer | F | Common Stock | 19505 | $4.88 | 261,414.0000 | 0 | 6.94% | 0.00% |
| March 9, 2024 | Barber Daniel | President and CEO | F | Common Stock | 56824 | $4.88 | 826,478.0000 | 0 | 6.43% | 0.00% |
| Aug. 9, 2024 | Kraus Carl N | Chief Medical Officer | F | Common Stock | 10819 | $3.43 | 251,681.0000 | 0 | 4.12% | 0.00% |
| June 20, 2024 | COSTA SANTO J | Not found | A | Stock Option (Right to Purchase) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| June 20, 2024 | Taglietti Marco | Not found | A | Stock Option (Right to Purchase) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| June 20, 2024 | MORRIS TIMOTHY E | Not found | A | Stock Option (right to purchase) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| June 20, 2024 | BROWN GREGORY B | Not found | A | Stock Option (Right to Purchase) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| June 20, 2024 | Krop Julie | Not found | A | Stock Option (Right to Purchase) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| June 20, 2024 | Cochran John | Not found | A | Stock Option (Right to Purchase) | 38000 | $0.00 | 38,000.0000 | 0 | 9999.99% | 0.00% |
| June 7, 2024 | Korczynski Sherry | SVP Sales and Marketing | A | Common Stock | 25000 | $0.00 | 25,000.0000 | 0 | 9999.99% | 0.00% |
| May 10, 2024 | Jenkins Abigail L. | Not found | A | Non-Qualified Stock Option (right to buy) | 57000 | $0.00 | 57,000.0000 | 0 | 50.00% | 0.00% |
| May 10, 2024 | Wargacki Stephen | Chief Science Officer | A | Common Stock | 10000 | $0.00 | 267,963.0000 | 0 | 3.88% | 0.00% |
| March 15, 2024 | Schobel Alexander Mark | Chief Innovation/Tech Officer | S | Common Stock | 50000 | $6.00 | 984,476.0000 | 0 | 4.83% | 0.00% |
| March 9, 2024 | Schobel Alexander Mark | Chief Innovation/Tech Officer | F | Common Stock | 5895 | $4.88 | 1,034,476.0000 | 0 | 0.57% | 0.00% |
| March 9, 2024 | TOTH A ERNEST JR | SVP, Chief Financial Officer | F | Common Stock | 11705 | $4.88 | 248,295.0000 | 0 | 4.50% | 0.00% |
| March 9, 2024 | BRAENDER LORI J | SVP, General Counsel | F | Common Stock | 10530 | $4.88 | 313,231.0000 | 0 | 3.25% | 0.00% |
| March 9, 2024 | Boyd Peter E. | See Remark | F | Common Stock | 8370 | $4.88 | 237,628.0000 | 0 | 3.40% | 0.00% |
| March 9, 2024 | Barber Daniel | President and CEO | F | Common Stock | 37938 | $4.88 | 845,364.0000 | 0 | 4.30% | 0.00% |
| March 9, 2024 | Wargacki Stephen | SVP, Research & Development | F | Common Stock | 11269 | $4.88 | 259,650.0000 | 0 | 4.16% | 0.00% |
| March 10, 2024 | Wargacki Stephen | SVP, Research & Development | F | Common Stock | 1687 | $4.88 | 257,963.0000 | 0 | 0.65% | 0.00% |
| March 9, 2024 | Jung Cassie | SVP, Operations | F | Common Stock | 8300 | $4.88 | 240,930.0000 | 0 | 3.33% | 0.00% |
| March 10, 2024 | Jung Cassie | SVP, Operations | F | Common Stock | 1132 | $4.88 | 239,798.0000 | 0 | 0.47% | 0.00% |
| March 8, 2024 | Schobel Alexander Mark | Chief Innovation/Tech Officer | S | Common Stock | 25000 | $5.19 | 1,040,371.0000 | 0 | 2.35% | 0.00% |
| March 7, 2024 | Kraus Carl N | Chief Medical Officer | A | Common Stock | 112500 | $0.00 | 262,500.0000 | 0 | 75.00% | 0.00% |
| March 7, 2024 | Kraus Carl N | Chief Medical Officer | A | Non-Qualified Stock Option (right to buy) | 56250 | $0.00 | 56,250.0000 | 0 | 9999.99% | 0.00% |
| March 7, 2024 | Barber Daniel | President and CEO | A | Common Stock | 242600 | $0.00 | 883,302.0000 | 0 | 37.86% | 0.00% |
| March 7, 2024 | Barber Daniel | President and CEO | A | Non-Qualified Stock Option (right to buy) | 363900 | $0.00 | 363,900.0000 | 0 | 9999.99% | 0.00% |
| March 10, 2023 | Jung Cassie | SVP, Operations | F | Common Stock | 1365 | $0.00 | 147,980.0000 | 0 | 0.91% | 0.00% |
| March 7, 2024 | Jung Cassie | SVP, Operations | A | Common Stock | 101250 | $0.00 | 249,230.0000 | 0 | 68.42% | 0.00% |
| March 7, 2024 | Jung Cassie | SVP, Operations | A | Non-Qualified Stock Option (right to buy) | 50625 | $0.00 | 50,625.0000 | 0 | 9999.99% | 0.00% |
| March 7, 2024 | Boyd Peter E. | See Remark | A | Common Stock | 86250 | $0.00 | 245,998.0000 | 0 | 53.99% | 0.00% |
| March 7, 2024 | Boyd Peter E. | See Remark | A | Non-Qualified Stock Option (right to buy) | 43125 | $0.00 | 43,125.0000 | 0 | 9999.99% | 0.00% |
| March 10, 2023 | Wargacki Stephen | SVP, Research & Development | F | Common Stock | 1981 | $0.79 | 158,419.0000 | 0 | 1.24% | 0.00% |
| March 7, 2024 | Wargacki Stephen | SVP, Research & Development | A | Common Stock | 112500 | $0.00 | 270,919.0000 | 0 | 71.01% | 0.00% |
| March 7, 2024 | Wargacki Stephen | SVP, Research & Development | A | Non-Qualified Stock Option (right to buy) | 56250 | $0.00 | 56,250.0000 | 0 | 9999.99% | 0.00% |
| March 7, 2024 | BRAENDER LORI J | SVP, General Counsel | A | Common Stock | 135000 | $0.00 | 323,761.0000 | 0 | 71.52% | 0.00% |
| March 7, 2024 | BRAENDER LORI J | SVP, General Counsel | A | Non-Qualified Stock Option (right to buy) | 67500 | $0.00 | 67,500.0000 | 0 | 9999.99% | 0.00% |
| March 7, 2024 | TOTH A ERNEST JR | SVP, Chief Financial Officer | A | Common Stock | 120000 | $0.00 | 260,000.0000 | 0 | 85.71% | 0.00% |
| March 7, 2024 | TOTH A ERNEST JR | SVP, Chief Financial Officer | A | Non-Qualified Stock Option (right to buy) | 60000 | $0.00 | 60,000.0000 | 0 | 9999.99% | 0.00% |
| March 7, 2024 | Schobel Alexander Mark | Chief Innovation/Tech Officer | A | Common Stock | 82500 | $0.00 | 1,065,371.0000 | 0 | 8.39% | 0.00% |
| March 7, 2024 | Schobel Alexander Mark | Chief Innovation/Tech Officer | A | Non-Qualified Stock Option (right to buy) | 41250 | $0.00 | 41,250.0000 | 0 | 9999.99% | 0.00% |